These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 30116943)
1. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Cheema PK; Thawer A; Leake J; Cheng SY; Khanna S; Charles Victor J Support Care Cancer; 2019 Mar; 27(3):1029-1039. PubMed ID: 30116943 [TBL] [Abstract][Full Text] [Related]
2. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. Khrystolubova N; Shieh M; Patel AJ; Bailey R J Oncol Pharm Pract; 2020 Jan; 26(1):13-22. PubMed ID: 30832554 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453 [TBL] [Abstract][Full Text] [Related]
4. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623 [TBL] [Abstract][Full Text] [Related]
5. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Imai H; Kaira K; Suzuki K; Anzai M; Tsuda T; Ishizuka T; Kuwako T; Naruse I; Nemoto K; Uchino J; Morozumi N; Ishihara S; Minato K; Hisada T Lung Cancer; 2018 Dec; 126():41-47. PubMed ID: 30527191 [TBL] [Abstract][Full Text] [Related]
7. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668 [TBL] [Abstract][Full Text] [Related]
8. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Engle JA; Kolesar JM Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236 [TBL] [Abstract][Full Text] [Related]
9. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Takeda M; Okamoto I; Nakagawa K Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957 [TBL] [Abstract][Full Text] [Related]
10. [Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)]. Iwata K; Ryota N; Hikita A; Sando M; Suzuki H; Tamiya M; Azuma Y; Tani E; Hamaguchi M; Tanaka A; Shiroyama T; Morishita N; Okamoto N; Futagami S; Hirashima T Gan To Kagaku Ryoho; 2015 Aug; 42(8):967-72. PubMed ID: 26321711 [TBL] [Abstract][Full Text] [Related]
11. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626 [TBL] [Abstract][Full Text] [Related]
12. Skin Rash Can Be a Useful Marker for Afatinib Efficacy. Nasu S; Suzuki H; Shiroyama T; Tanaka A; Iwata K; Ryota N; Ueda Y; Takata SO; Masuhiro K; Morita S; Morishita N; Okamoto N; Hirashima T Anticancer Res; 2018 Mar; 38(3):1783-1788. PubMed ID: 29491117 [TBL] [Abstract][Full Text] [Related]
13. Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Goto A; Ozawa Y; Koda K; Akahori D; Koyauchi T; Amano Y; Kakutani T; Sato Y; Hasegawa H; Matsui T; Yokomura K; Suda T Respir Investig; 2018 Mar; 56(2):179-183. PubMed ID: 29548657 [TBL] [Abstract][Full Text] [Related]
14. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629 [TBL] [Abstract][Full Text] [Related]
15. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib]. Taus Á Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246 [TBL] [Abstract][Full Text] [Related]
16. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249 [TBL] [Abstract][Full Text] [Related]
17. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. Wada Y; Koyama S; Kuraishi H; Miyahara T; Yoshiike F; Agatsuma T; Yamamoto R; Ono Y; Suzuki T; Hachiya T; Gomi D; Tateishi K; Hanaoka M; Koizumi T Respir Investig; 2016 Nov; 54(6):462-467. PubMed ID: 27886858 [TBL] [Abstract][Full Text] [Related]
18. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023 [TBL] [Abstract][Full Text] [Related]
20. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. Tamura K; Nukiwa T; Gemma A; Yamamoto N; Mizushima M; Ochai K; Ikeda R; Azuma H; Nakanishi Y Int J Clin Oncol; 2019 Aug; 24(8):917-926. PubMed ID: 30953238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]